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The National Cancer Registry (NCR) within the 
National Health Laboratory Service (NHLS) is the 
principal cancer surveillance system in South Africa 
(SA) and maintains the largest repository of cancer 
data in the country. The NCR is mandated through 
recent (2011) legislation to monitor SA’s national cancer burden.[1] 
Established in 1986 as a voluntary, pathology-based cancer reporting 
system, it now receives over 100 000 cancer reports annually. 
Approximately 80 000 are new cases, on the basis of which cancer 
incidence is calculated. Data collected from the system are used for 
research, for educational purposes and to inform decision-making for 
cancer prevention and control policies in SA.
Surveillance and research activities at the NCR have made a 
significant contribution to the scope of cancer knowledge both locally 
and internationally. In addition to describing the overall cancer 
burden in SA, the registry data have been used to highlight cancers 
of special interest such as skin, prostate and oral cancers.[2-4] Of 
importance in the SA context, the data from the Johannesburg Cancer 
Case Control Study (JCCCS), conducted by the research arm of the 
NCR, the Cancer Epidemiology Research Group (CERG), have been 
used to extensively describe the epidemiology of HIV-related cancers 
in SA and particularly to explore the relationship between Kaposi’s 
sarcoma and HIV.[5-11] The JCCCS has also contributed to risk factor 
analysis in the International Collaboration of Epidemiological Studies 
of Cervical Cancer, including the link between oral and injectable 
contraceptive use and female cancers.[12-18] 
The NCR manages cancer surveillance in the context of a dual 
health system in SA: a large public health infrastructure serving 
approximately 84% of the population, and a smaller private health 
system catering to 16%.[19] The NCR achieves its objectives by 
estimating cancer incidence rates by age, race and gender, using 
pathology reports received from all public and private healthcare 
laboratories nationally.[20]
Data reporting among private systems was consistent throughout 
the early 2000s. However, concerns regarding voluntary sharing of 
patient data led some private healthcare laboratories to withhold 
cancer pathology reports, beginning in 2005. We undertook an 
analysis to measure the impact of withheld private data on cancer 
surveillance in SA.
Methods
NCR methodology
The NCR methodology follows that recommended by the International 
Agency for Research on Cancer.[21] Pathology reports are received in 
electronic or hard-copy format, and from these appropriate data 
items, namely demographic and tumour information, are abstracted. 
A hot-deck imputation method[22] is used to allocate population 
group to cases without this information. Following international 
practice, cancers are classified by anatomical site/topography using 
the International Classification of Diseases – Oncology, Version 3 
(ICD-O-3).[23]
Mid-year population estimates from Statistics South Africa are 
used as the denominator, stratified by population, gender and 
5-year age groups. Analyses include crude incidence rates, age-
standardised incidence rates (ASRs) using the Doll et al.[24] world 
population as the standard, 95% confidence intervals for the ASRs, 
and cumulative lifetime incidence risk (the likelihood of developing 
a cancer in one’s lifetime if one lives to age 74).[25] The ASR and 
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the lifetime incidence risk are adjusted for 
the proportion of cases in the unknown 
age category. The rate calculations represent 
incident cancers, excluding basal and 
squamous cell carcinomas of the skin.
Analysis of under-reporting
Using actual numbers of cases reported by 
private health laboratories for 1995 - 2004, 
a linear regression analysis was performed. 
Based on this analysis, we were able to project 
the expected cases for 2005, 2006 and 2007 
from private laboratories. The calculated 
number of projected cases for each year 
was used to estimate the number of missed 
cases reported per annum from private 
laboratories. Differences between actual and 
projected figures were calculated to establish 
the percentage of under-reporting.
Results
In 1995, a total of 46 769 cases of cancer 
were reported from all laboratories (both 
private and public system laboratories), 
which increased to 52 887 cases in 2004, then 
decreased to 52 816 in 2007 (Fig. 1). The 
projected increase in cases in 2005 was 53 407 
(3.8% net increase from actual cases reported), 
followed by 56 679 (3.5% net increase) in 2006 
and 54 823 (3.7% net increase) in 2007.
In 1995, a total of 19 137 cases of cancer 
were reported from private laboratories, 
which increased to 24 473 cases in 2004, 
then decreased to 19 803 in 2007. The 
projected number of reported cases of cancer 
in 2005 was 26 359 (19.7% net increase from 
actual cases reported), followed by 27  012 
(18.8% net increase) in 2006 and 27  666 
(28.4% net increase) in 2007.
Discussion
This is the first study to assess the impact of 
missing cancer cases from private healthcare 
laboratories on NCR surveillance in SA. 
While private healthcare reporting decreased 
by 28% from 2005 to 2007, this represented a 
minimal impact on overall cancer reporting 
(net decrease of <4%). Despite missing data, 
the NCR cancer data therefore provide an 
accurate estimation of overall pathology-
diagnosed cancer incidence in SA.
This finding can be explained by healthcare 
use patterns, particularly the two-tiered 
healthcare system mentioned previously. 
Given that a relatively large proportion of 
the population accesses the public healthcare 
system (84%) as opposed to private healthcare 
facilities,[19] the bulk of cancer reports to the 
NCR originate in the public health system 
from the more than 300 laboratories operated 
by the NHLS. While the overall decrease in 
reporting may represent a small proportion, 
missing data may be over-represented in 
certain population groups. Membership in 
medical schemes, and therefore ability to 
access private healthcare, is concentrated in 
the wealthiest 20% of the SA population[26] 
and correlates with population group. More 
than two-thirds of white South Africans 
belong to a medical aid, as opposed to 8% of 
blacks.[27] The NCR may therefore be under-
reporting cancers in these groups for the 
specified period.
Our results also reflect some under-
reporting or under-diagnosis of cancer 
among public healthcare facilities. Sixteen 
per cent of South Africans (all race groups) 
belong to a medical aid,[19] yet the private 
health service represents just under half 
of the cancer cases reported. Despite the 
lifestyle risk factors for cancer associated 
with higher socioeconomic status, one 
would expect more cancer cases from the 
public health service than the approximately 
40 000 received by the NCR. The NCR 
receives and processes all cancer pathology 
reports from the public healthcare facilities. 
The rate of under-diagnosis and under-
ascertainment of cancers in the SA health 
service must be quantified so that a more 
accurate illustration of the cancer burden 
can be provided.
Several strengths and limitations are 
evident in this study. The NCR is the largest 
and most representative cancer surveillance 
system in SA. The registry methods are robust, 
with staff available to process the country’s 
cancer burden with a quality-assured 
output. Since the registry is pathology based, 
specific and detailed histological diagnoses 
are available. However, this also implies 
that cases without a pathology diagnosis 
will be missed, resulting in underestimates 
of cancer burden. Although publication of 
cancer incidences for SA is delayed, the 
reporting time will soon be comparable to 
more comprehensive international registries 
such as the US Centers for Disease Control’s 
National Program of Cancer Registries, 
which has a reporting time of approximately 
3 years from the time a patient is diagnosed 
to the time national data are reported.[28]
The delays in cancer reporting are 
attributable to a number of factors, including 
lack of a champion for cancer registration. 
The NCR was without a director from 2002 to 
2009, which led to leadership inconsistencies 
and high staff turnover. During this time, 
competing health priorities such as HIV 
prevention and control emerged as the 
public health priority in SA. As a result, 
the NCR did not receive the same level of 
resources for cancer surveillance as in the 
past, which impacted negatively on cancer 
reporting and data analysis.
However, with the appointment of the 
new management in 2009 and promulgation 
of new legislation in 2011, there have been 
significant gains in efficiency. The NCR has 
established electronic receipt of pathology 
data from public sector laboratories, 
thereby ensuring a more timely acquisition 
of morbidity information. Relationships 
with private sector laboratories have 
been renewed, and a standard system has 
been established to receive private sector 
pathology data electronically.
Promulgation of Regulation 380 of the 
National Health Act[1] by the Department of 
Health in 2011 marked a milestone in cancer 
care and control by formally establishing the 
NCR as the main cancer surveillance agency 
and requiring mandatory reporting of all 
confirmed cancers in SA to the NCR. The 
legislation ensured that cancer reporting 
to the NCR was no longer voluntary and 
precluded the drop-off of reporting that has 
occurred in the past.
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Fig. 1. Actual and projected case reporting from private laboratories and to the NCR, 1995 - 2007.
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Regulation 380 also allows the NCR to implement population-based 
cancer registration in selected surveillance sites. In response to the 
legislation, the NCR has developed a 10-year business plan for the 
implementation of the population-based registries for the country, as 
well as tackling the pathology-based registry backlog. Fund-raising 
activities have commenced, and a pilot population-based registry is 
operational in Ekurhuleni District, Gauteng Province. Population- 
and pathology-based cancer registration complemented by novel 
research from the NCR’s CERG will provide a comprehensive 
description of the cancer burden across SA.
In an era of growing prioritisation of non-communicable dis-
eases, and with global cancer burdens estimated to increase signi-
ficantly,[29] the NCR has an invaluable role to play in the health and 
health planning landscape of SA. In view of the progressive health 
developments in the country, such as introduction of National Health 
Insurance,[5] there is an imperative to accurately quantify the cancer 
burden, and thus the cost of cancer services to be provided to the SA 
population.
Conclusion
The withholding of private laboratory cancer data from 2005 to 2007 
resulted in a 4% decrease in overall cancer reporting to SA’s NCR, 
despite a relatively larger amount (28%) of under-reporting of private 
healthcare cancers. This probably reflects the reality that four out of 
every five SA citizens receive care in the public healthcare system. 
This analysis does not address undiagnosed cancer cases in the 
public health system, an issue that requires further investigation. The 
NCR is an invaluable source of cancer data for the country. Recent 
parliamentary legislation, investment in the NCR and improved 
access to quality healthcare will allow the NCR to remain SA’s leading 
resource for national cancer data.
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